Healio

Pfizer will seek approval for its Lyme disease vaccine

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...
Fierce Biotech

Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...
Becker's Hospital Review

Pfizer Lyme vaccine candidate heads to FDA

Pfizer Lyme vaccine candidate shows over 70% efficacy in phase 3 trial and moves forward with FDA regulatory submission.

Pfizer, Valneva report strong efficacy data from Lyme vaccine trial

Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study ...
Cadillac News

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

Pfizer touts promising survival data without worsening for advanced breast cancer patients

Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...